LINCS MCF 10A Common Project: Rolling-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Dataset 1 of 15: End-point cell counts and normalized growth rate inhibition values for all technical replicates of biological replicate 1. - Dataset (ID:20309)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Time Point (hr) | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value | Assay Plate | Assay Well |
|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 63.39 | 770.25 | 1236 | 9326 | 0.1325 | 0.1405 | MN20160304_L02 | J14 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 63.39 | 770.25 | 811 | 9326 | 0.0870 | 0.0144 | MN20160304_L02 | K04 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 65.61 | 770.25 | 1239 | 9736 | 0.1273 | 0.1387 | MN20160304_L02 | J14 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 65.61 | 770.25 | 753 | 9736 | 0.0773 | -0.0062 | MN20160304_L02 | K04 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 67.83 | 770.25 | 1301 | 10078 | 0.1291 | 0.1518 | MN20160304_L02 | J14 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 67.83 | 770.25 | 702 | 10078 | 0.0697 | -0.0247 | MN20160304_L02 | K04 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 70.05 | 770.25 | 1330 | 10413 | 0.1277 | 0.1565 | MN20160304_L02 | J14 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 70.05 | 770.25 | 647 | 10413 | 0.0621 | -0.0454 | MN20160304_L02 | K04 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 72.27 | 770.25 | 1343 | 10730 | 0.1252 | 0.1575 | MN20160304_L02 | J14 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 72.27 | 770.25 | 592 | 10730 | 0.0552 | -0.0669 | MN20160304_L02 | K04 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 74.50 | 770.25 | 1411 | 10991 | 0.1284 | 0.1710 | MN20160304_L02 | J14 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 74.50 | 770.25 | 563 | 10991 | 0.0512 | -0.0785 | MN20160304_L02 | K04 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 76.75 | 770.25 | 1419 | 11262 | 0.1260 | 0.1710 | MN20160304_L02 | J14 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 76.75 | 770.25 | 498 | 11262 | 0.0442 | -0.1066 | MN20160304_L02 | K04 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 78.98 | 770.25 | 1475 | 11518 | 0.1281 | 0.1812 | MN20160304_L02 | J14 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 78.98 | 770.25 | 463 | 11518 | 0.0402 | -0.1223 | MN20160304_L02 | K04 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 81.20 | 770.25 | 1405 | 11766 | 0.1194 | 0.1651 | MN20160304_L02 | J14 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 81.20 | 770.25 | 420 | 11766 | 0.0357 | -0.1429 | MN20160304_L02 | K04 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 83.42 | 770.25 | 1517 | 12031 | 0.1261 | 0.1864 | MN20160304_L02 | J14 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 83.42 | 770.25 | 380 | 12031 | 0.0316 | -0.1632 | MN20160304_L02 | K04 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 85.64 | 770.25 | 1553 | 12287 | 0.1264 | 0.1918 | MN20160304_L02 | J14 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 85.64 | 770.25 | 339 | 12287 | 0.0276 | -0.1857 | MN20160304_L02 | K04 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 87.86 | 770.25 | 1644 | 12543 | 0.1311 | 0.2073 | MN20160304_L02 | J14 |
| MCF 10A-H2B-mCherry | Neratinib | 3.1623 | 87.86 | 770.25 | 299 | 12543 | 0.0238 | -0.2095 | MN20160304_L02 | K04 |
| MCF 10A-H2B-mCherry | Palbociclib | 0.0010833 | 3.21 | 770.25 | 888 | 904 | 0.9816 | 0.8463 | MN20160304_L02 | D21 |